文献速递神经肿瘤

伽玛刀放射外科治疗无功能性和激素活性垂体腺瘤的长期结局

Long-Term Outcome of Nonfunctioning and Hormonal Active Pituitary Adenoma After Gamma Knife Radiosurgery.
PubMed 文献 · World Neurosurg · 2018-03-21

回顾性分析美国路易斯安那州立大学健康科学中心17年间111例组织学确诊垂体腺瘤接受伽玛刀放射外科治疗的患者,其中无功能性腺瘤87例、激素活性腺瘤24例。结果显示肿瘤生长控制率90%、肿瘤缩小率54%、进展停止率36%;生长激素腺瘤生化缓解率57%、促肾上腺皮质激素腺瘤67%、泌乳素瘤40%。年龄低于50岁和肿瘤体积小于5 cm3与有利的放射外科结局相关。

要点

  • 伽玛刀治疗后肿瘤生长控制率90%,肿瘤缩小率54%,进展停止率36%。
  • 生化缓解率:生长激素腺瘤57%、促肾上腺皮质激素腺瘤67%、泌乳素瘤40%。
  • 年龄低于50岁和肿瘤体积小于5 cm3与有利的放射外科结局相关。

核心结论

  • 伽玛刀放射外科在无功能性和激素活性垂体腺瘤治疗中起重要作用,肿瘤控制率高且邻近神经或内分泌轴损伤风险低。

研究设计与样本

  • 回顾性分析111例组织学确诊的垂体腺瘤患者,均在美国路易斯安那州立大学健康科学中心(Shreveport, Louisiana, USA)接受伽玛刀放射外科治疗,时间跨度为17年。
  • 根据内分泌特征将肿瘤分为无功能性腺瘤(87例)和激素活性腺瘤(24例)。
  • 使用SPSS软件22.0版进行相关统计分析。

主要发现

  • 患者中位年龄58岁;38例(34.2%)有垂体功能减退症状,8例(7%)有全垂体功能减退症状。
  • 伽玛刀治疗前平均肿瘤体积为3.8 cm3;28例(25.2%)有鞍上扩展,34例(30.6%)有海绵窦扩展。
  • 肿瘤缩小队列中观察到肿瘤体积缩小>70%,中位缩小时间为48.4个月;进展队列中肿瘤体积增大(伽玛刀前3.8 cm3 vs 伽玛刀后6.5 cm3)。
  • 70例(63.1%)神经功能改善,26例(23.4%)内分泌功能恶化。
  • 肿瘤生长控制率90%,肿瘤缩小率54%,进展停止率36%;生长激素分泌腺瘤生化缓解率57%,促肾上腺皮质激素腺瘤67%,泌乳素瘤40%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stereotactic radiosurgery (SRS), particularly Gamma Knife radiosurgery (GKRS) is an established treatment option for residual and recurrent pituitary adenoma tumors. It helps in the preservation of surrounding normal neuronal, vascular, and hormone-producing structures and causes fewer neurologic deficits. The aim of this research was to evaluate the efficacy and define the role of GKRS in the treatment of nonfunctioning (NFA) and hormonal active (HAA) pituitary adenoma. METHODS: A retrospective analysis of 111 patients with histologically proven pituitary adenoma who underwent GKRS treatment at Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA, over a 17-year period was conducted presented. The clinical and radiologic data were collected from the database. The tumors were categorized into NFA and HAA based on the endocrinology profile. The relevant statistical analysis was conducted with SPSS software, version 22.0. RESULTS: The median age of the patients was 58 years. The study comprised 87 patients with NFA and 24 patients with HAA tumors. Thirty-eight patients (34.2%) had hypopituitarism symptoms, and 8 patients (7%) had panhypopituitarism symptoms. The mean tumor volume before to GKRS was 3.8 cm3. Suprasellar and cavernous extension of the tumor was noted in 28 patients (25.2%) and 34 (30.6%) patients, respectively. We observed >70% reduction in the size of tumors in the shrinkage cohort after GKRS; the median time for shrinkage was 48.4 months. However, increase in tumor size was noted in the progression cohort (pre-GKRS 3.8 cm3 vs. post-GKRS 6.5 cm3). Seventy patients (63.1%) had neurologic improvement, and 26 patients (23.4%) had endocrinologic worsening after GKRS. CONCLUSIONS: GKRS plays a significant role in the treatment of NFA and HAA. It affords a high rate of tumor control and offers a low risk of collateral neurologic or endocrine axis injury. Our study shows that control of tumor growth was achieved in 90% of patients, shrinkage of tumor in 54%, and arrest of progression in 36% after GKRS treatment. The biochemical remission rate in growth hormone secreting adenoma was 57%, in adrenocorticotropic hormone adenoma 67%, and prolactinoma 40%. Age below 50 years and tumor volume less than 5 cm3 were associated with a favorable radiosurgical outcome.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Narayan V, Mohammed N, Bir SC, et al. Long-Term Outcome of Nonfunctioning and Hormonal Active Pituitary Adenoma After Gamma Knife Radiosurgery. World Neurosurg. 2018. PMID: 29574220. doi:10.1016/j.wneu.2018.03.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。